Significantly different coagulation factor activities underlying the variability of 'normal' activated partial thromboplastin time

Blood Coagulation and Fibrinolysis

Volumn 23, Issue 1, 2012, Pages 35-38

  Park, Kyoung Jin ^a   Kwon, Eui Hoon ^a   Ma, Youngeun ^a   Park, In Ae ^b   Kim, Seon Woo ^b   Kim, Sun Hee ^a   Kim, Hee Jin ^a  

^a Sungkyunkwan University   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

activated partial thromboplastin time; coagulation factors; population; reference interval

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; PROTHROMBIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REFERENCE VALUE;

BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; POLYMORPHISM, GENETIC; REFERENCE VALUES;

EID: 84855203353     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32834a6136     Document Type: Article

References (24)

1. LippiG, Favaloro EJ. Activated partial thromboplastin time: New tricks for an old dogma. Semin Thromb Hemost 2008; 34:604-611.
2. Hron G, Eichinger S, Weltermann A, Quehenberger P, Halbmayer WM, Kyrle PA. Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. J Thromb Haemost 2006; 4:752-756.
3. Korte W, Clarke S, Lefkowitz JB. Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism. Am J Clin Pathol 2000; 113:123-127. (Pubitemid 30217347)
4. Legnani C, Mattarozzi S, Cini M, Cosmi B, Favaretto E, Palareti G. Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. Br J Haematol 2006; 134:227-232. (Pubitemid 43893916)
5. Lippi G, Salvagno GL, Ippolito L, Franchini M, Favaloro EJ. Shortened activated partial thromboplastin time: Causes and management. Blood Coagul Fibrinolysis 2010; 21:459-463.
6. Madi AM, Greci LS, Nawaz H, Katz DL. The activated partial thromboplastin time in early diagnosis of myocardial infarction. Blood Coagul Fibrinolysis 2001; 12:495-499. (Pubitemid 32803690)
7. Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci PM. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 2004; 104:3631-3634. (Pubitemid 39564438)
8. Mina A, Favaloro EJ, Mohammed S, Koutts J. A laboratory evaluation into the short activated partial thromboplastin time. Blood Coagul Fibrinolysis 2010; 21:152-157.
9. Ten Boekel E, Bartels P. Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1+2, D-dimer and FVIII:C. Pathophysiol Haemost Thromb 2002; 32:137-142. (Pubitemid 37490505)
10. Pouplard C, Trossaert M, LEA Querrec, Delahousse B, Giraudeau B, Gruel Y. Influence of source of phospholipids for APTT-based factor IX assays and potential consequences for the diagnosis of mild haemophilia B. Haemophilia 2009; 15:365-368.
11. Ten Boekel E, Bock M, Vrielink GJ, Liem R, Hendriks H, de Kieviet W. Detection of shortened activated partial thromboplastin times: An evaluation of different commercial reagents. Thromb Res 2007; 121:361-367.
12. Park CH, Seo JY, Kim HJ, Jang JH, Kim SH. A diagnostic challenge: Mild hemophilia B with normal activated partial thromboplastin time. Blood Coagul Fibrinolysis 2010; 21:368-371.
13. Abdullah WZ, Moufak SK, Yusof Z, Mohamad MS, Kamarul IM. Shortened activated partial thromboplastin time, a hemostatic marker for hypercoagulable state during acute coronary event. Transl Res 2010; 155:315-319.
14. Cushman M, O'Meara ES, Folsom AR, Heckbert SR. Coagulation factors IX through XIII and the risk of future venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology. Blood 2009; 114:2878-2883.
15. Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L. Crosslaboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors. Blood Coagul Fibrinolysis 2005; 16:597-605. (Pubitemid 41658981)
16. Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L, Favaloro JW. Reassessment of ABO blood group, sex, and age on laboratory parameters usedtodiagnosevonWillebranddisorder:potentialinfluenceonthediagnosis vs the potential association with risk of thrombosis. Am J Clin Pathol 2005; 124:910-917. (Pubitemid 41740192)
17. Mari D, Coppola R, Provenzano R. Hemostasis factors and aging. Exp Gerontol 2008; 43:66-73.
18. Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, Hamasaki N, et al. A common genetic polymorphism (46Cto T substitution) in the 5'-untranslated region of the coagulation factor XII gene is associated with lowtranslation efficiency and decrease in plasma factor XII level. Blood 1998; 91:2010-2014. (Pubitemid 28185502)
19. Corral J, Anton AI, Quiroga T, Gonzalez-Conejero R, Pereira J, Roldan V, et al. Influence of the F12-4 C>T polymorphism on hemostatic tests. Blood Coagul Fibrinolysis 2010; 21:632-639.
20. Viel KR, Machiah DK, Warren DM, Khachidze M, Buil A, Fernstrom K, et al. A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood 2007; 109:3713-3724. (Pubitemid 46641720)
21. Scanavini D, Legnani C, Lunghi B, Mingozzi F, Palareti G, Bernardi F. The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels. Thromb Haemost 2005; 93:453-456. (Pubitemid 40392532)
22. JangJH,SeoJY,BangSH,ParkIA, KimHJ,KimSH.Establishment ofreference intervals for von Willebrand factor antigen and eight coagulation factors in a Korean population following the Clinical and Laboratory Standards Institute guidelines. Blood Coagul Fibrinolysis 2010; 21:251-255.
23. Sotiriadis A, Makrigiannakis A, Stefos T, Paraskevaidis E, Kalantaridou SN. Fibrinolytic defects and recurrent miscarriage: A systematic review and meta-analysis. Obstet Gynecol 2007; 109:1146-1155. (Pubitemid 46685960)
24. Bach J, Endler G, Winkelmann BR, Boehm BO, Maerz W, Mannhalter C, et al. Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk. J Thromb Haemost 2008; 6:291-296.